The Changing Landscape of Biopharma Finance

A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.

Sales and marketing effectiveness of speaker programs is often one of the least understood aspects in the industry. Yet, pharma brands spent over $12.5 billion in 2022 to engage and influence with HCP-to-HCP activities. CMS’s Open Payments data is an overlooked tool to get greater visibility and create more strategic opportunities—while also enriching compliance. This paper explores how to filter and pinpoint critical data sets using browser-based technology to gain marketing insights from this data and measure competitiveness.¬

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.

Pharma leaders are increasingly allocating budget toward real-time clinical alerts that integrate with and improve patient care. By investing in algorithms that auto-detect diseases as common as heart failure and as rare as pulmonary arterial hypertension, manufacturers can help accelerate time to diagnosis and treatment, streamline monitoring and identify new patients while starting them on the right therapies faster.